-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KN0YMveqjpaDxd1PfxU+FUdxPrUoEFEscMU1YphEVE8pkkXiHe8O3SrwvKvyhyjO 4wt57DXqMGOdi5yxJPj2YQ== 0001019687-05-003492.txt : 20051228 0001019687-05-003492.hdr.sgml : 20051228 20051227200305 ACCESSION NUMBER: 0001019687-05-003492 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20051227 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20051228 DATE AS OF CHANGE: 20051227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SIMULATIONS PLUS INC CENTRAL INDEX KEY: 0001023459 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373] IRS NUMBER: 954595609 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32046 FILM NUMBER: 051287769 BUSINESS ADDRESS: STREET 1: 1220 W. AVENUE J STREET 2: * CITY: LANCASTER STATE: CA ZIP: 93534-2902 BUSINESS PHONE: 661-723-7723 MAIL ADDRESS: STREET 1: 1220 W. AVENUE J CITY: LANCASTER STATE: CA ZIP: 93534-2902 8-K 1 simulations_8k-122705.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 December 27, 2005 (Date of the earliest event reported) Simulations Plus, Inc. ---------------------- (Exact name of Registrant as specified in its charter) California 001-32046 95-4595609 ---------- --------- ---------- (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification No.) 1220 West Avenue J, Lancaster, California 93534 ----------------------------------------------- (Address of principal executive offices) (Zip Code) (661) 723-7723 -------------- Registrant's telephone number, including area code ITEM 8.01 OTHER EVENTS. On December 27, 2005, Simulations Plus, Inc. (AMEX: SLP) announced that it has received a purchase order for the renewal of a global license for a specified number of users at six sites in the U.S., Europe, and Japan for a very large pharmaceutical company. ITEM 9.01 EXHIBITS AND REPORTS ON FORM 8-K. (a) Exhibits 99.1 Press release dated December 27, 2005 Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SIMULATIONS PLUS, INC. Dated: December 27, 2005 By: /s/ Momoko Beran ----------------------- Momoko A. Beran Chief Financial Officer EXHIBITS INDEX -------------- Exhibit Number Description -------------- ----------- 99.1 Press release, dated December 27, 2005 EX-99.1 2 simulations_8kex99-1.txt PRESS RELEASE EXHIBIT 99.1 SIMULATIONS PLUS Integrating Science and Software For Further Information: SIMULATIONS PLUS, INC. 1220 W. Avenue J Lancaster, CA 93534-2902 661.723.7723 www.simulations-plus.com CONTACT: Investor Relations Ms. Renee Bouche Simulations Plus, Inc. 661.723.7723 info@simulations-plus.com For Immediate Release: December 27, 2005 SIMULATIONS PLUS RENEWS IMPORTANT GLOBAL SOFTWARE LICENSE LARGE CUSTOMER RENEWS ANNUAL GLOBAL LICENSE FOR GASTROPLUS(TM) LANCASTER, CA, DECEMBER 27, 2005 - Simulations Plus, Inc. (AMEX: SLP), a leading provider of ADMET absorption simulation and structure-to-property prediction software for pharmaceutical discovery and development, announced that it has received a purchase order from a very large pharmaceutical company for the renewal of a global license for a specified number of users at six sites in the U.S., Europe, and Japan. Ron Creeley, vice president of marketing and sales of Simulations Plus, said: "This renewal is not one of the multi-year licenses that expire this fiscal year, but at a value of hundreds of thousands of dollars to one of the top three pharmaceutical companies in the world, it is a significant renewal sale. Last year, this customer's order came in our first fiscal quarter but was timed to expire at the end of the calendar year. Now, we have received the renewal for the coming calendar year. This order covers only our GastroPlus software and extension modules, including our newly released PBPKPlus Module, for a specific number of users. Interest in our GastroPlus products continues to grow among this client's scientists. We expect demand for additional GastroPlus licenses to grow. In addition, we anticipate licensing our new DDDPlus software at several of this customer's research sites this calendar year and look forward to presenting our new ClassPharmer(TM) product line to the client's research chemists beginning in February." ABOUT SIMULATIONS PLUS, INC. Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM), which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California. For more information, visit our Web site at www.simulations-plus.com. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 - - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: actual acceptance and licensing of the PBPKPlus Module, the ability of the Company to maintain its competitive advantage, the general economics of the pharmaceutical and assistive technology industries, the ability of the Company to attract and retain sufficient scientific and technical staff to sustain its R&D and customer support functions, the continued high renewal rate for the Company's software licenses, and a sustainable market. Further information on the Company's risk factors is contained in the Company's quarterly and annual reports as filed with the Securities and Exchange Commission. ### -----END PRIVACY-ENHANCED MESSAGE-----